Updated: Sep 18
Introduction
Finding the best leukemia hospitals in China has become a growing priority for international patients as the country's top oncology centers gain global recognition for advanced blood cancer care, particularly CAR-T cell therapy for relapsed or refractory leukemia. With NMPA-approved treatments, Grade 3A certified facilities, and costs that are often significantly lower than comparable care in the US, Australia, or Europe, more patients are looking to China as a serious option — not a last resort. This guide breaks down which hospitals lead in leukemia treatment, what sets them apart clinically, and what international patients need to know before making the decision to seek care abroad.
This guide profiles the five Chinese hematology programs with the highest leukemia case volume and the broadest transplant and cellular therapy infrastructure: Institute of Hematology at the Chinese Academy of Medical Sciences (Tianjin), Lu Daopei Hospital (Beijing), Peking University People's Hospital (Beijing), Shanghai Ruijin Hospital, and West China Hospital of Sichuan University (Chengdu). For each center, the article documents the leukemia subtypes it treats most often, the transplant and CAR-T platforms it operates, the donor and access constraints those platforms were developed to address, and how an international referral is structured — from initial case submission through visa invitation to admission. The selection criteria are stated in the next section.
Clinical Scope of Chinese Leukemia Centers
Most cases handled by these centers fall into four buckets:
Relapsed/refractory B-ALL or T-ALL in children and young adults, including post-transplant relapse.
High-risk AML and secondary AML, including complex cytogenetics, AML-MRC, and AML with myelodysplasia-related changes.
Ph+ ALL and Ph-like ALL in adolescent and young adult patients.
Transplant-eligible leukemia without a fully HLA-matched donor — the indication that has driven the development of China's haploidentical transplant infrastructure.
CAR-T for B-cell hematologic malignancies is available at all five centers below, but the platforms and indication coverage vary. T-cell leukemia (CD7, CD5) is more narrowly distributed and tends to concentrate at Lu Daopei and the Beijing centers. Myeloma and lymphoma pathways are covered in separate articles (cross-linked at the bottom).
How These Centers Were Selected
Five inclusion criteria were applied, all sourceable, to identify the best leukemia hospitals in China for international referrals:
Dedicated hematology department with leukemia-specific bed allocation rather than a generalist oncology service.
Documented transplant volume in allogeneic HSCT of at least 100 cases per year.
Active CAR-T program for at least one hematologic indication — autologous or investigator-initiated.
International patient office with English-language coordinators and a documented visa medical invitation process.
Peer-reviewed publication activity in the last three years in journals indexed for hematology or transplant.
Centers that meet these criteria but are not listed (e.g., the 307 Hospital transfusion program, the First Affiliated Hospital of Zhejiang University hematology service) are excluded because the international referral pathway has not been independently verified through a completed case.
The Five Highest-Volume Leukemia Programs in China
The list is ordered alphabetically by institution name to keep the structure neutral; clinical matching by subtype is handled in the decision table further down.
Institute of Hematology, Chinese Academy of Medical Sciences (IHS-CAMS) — Tianjin
IHS-CAMS is China's national hematology research institute and operates one of the country's largest leukemia services. The clinical arm is based in Tianjin, with referral inflow from across northern China.
Clinical profile.
AML is the highest-volume diagnosis, including AML-MRC, complex karyotype AML, and therapy-related AML.
MDS and AML transformation are a documented second-pillar program.
Pediatric and adult cohorts run in parallel.
Active research output through the CAMS publication track on AML and MDS prognosis.
Transplant platforms. Matched sibling, matched unrelated, and haploidentical; cord blood is used selectively. CAR-T for B-ALL is available through the institutional protocol; cellular therapy for T-ALL is more limited and tends to route elsewhere.
International referral. Referrals for adult AML and MDS with complex disease biology are a high-fit indication. Pediatric cases with very high-risk cytogenetics also route here, although the dedicated pediatric hematology hospital track at Lu Daopei is often preferred for transplant planning specifically.
Lu Daopei Hospital — Beijing
Lu Daopei Hospital is a dedicated hematology hospital founded in 2011, with both adult and pediatric inpatient services concentrated in leukemia, lymphoma, MDS, and transplant. It runs one of the higher-volume allogeneic transplant programs in the country and has built out a cellular therapy track that is unusual in its breadth across hematologic indications.
Clinical profile.
Pediatric and adult B-ALL and T-ALL (the latter including CD7-directed protocols).
Relapsed/refractory acute leukemia after first-line therapy, including post-transplant relapse.
Pediatric AML and infant leukemia.
Aplasia and marrow-failure syndromes with HSCT indication.
Transplant platforms. Autologous, matched sibling, matched unrelated, haploidentical, and cord blood. CAR-T programs span CD19 (B-ALL, DLBCL), BCMA (myeloma), CD7 and CD5 (T-ALL, T-cell lymphoma), and selected dual-target constructs for relapsed lymphoma. The CAR-T volume for leukemia specifically is among the highest at any single Chinese center.
International referral. High-fit indications include pediatric B-ALL or T-ALL where standard chemotherapy has not produced durable MRD-negative remission, and cases where CD7 CAR-T or CD19 CAR-T has been recommended or already started abroad. The hospital also sees a significant caseload of international patients with relapsed AML where transplant with an alternative donor is planned.
Peking University People's Hospital (PUPH) — Beijing
PUPH runs the Peking University Institute of Hematology, which has been the principal academic driver of China's haploidentical transplant program since the early 2000s. The transplant protocol structure — including the use of ATG-based conditioning and post-transplant cyclophosphamide-based GVHD prophylaxis in adult recipients — is widely cited internationally.
Clinical profile.
Adult acute leukemia (ALL, AML, mixed phenotype).
Adult MDS and CML in advanced phase.
Ph+ ALL with TKI-based induction followed by transplant.
Post-transplant relapse management, including donor lymphocyte infusion programs.
Transplant platforms. Matched sibling, matched unrelated, haploidentical (the largest such program globally for adult recipients), and cord blood. CAR-T for B-ALL, DLBCL, and multiple myeloma is run through the hematology department's cellular therapy program.
International referral. Best fit for adult patients with a confirmed transplant plan where donor source is the main question — particularly when only a haploidentical or mismatched unrelated donor is available. Pediatric cases typically route to Lu Daopei because of the dedicated pediatric service structure rather than a generalist oncology pathway.
Shanghai Ruijin Hospital — Shanghai
Ruijin is affiliated with Shanghai Jiao Tong University School of Medicine and operates one of the eastern-China reference hematology services. The department runs autologous and allogeneic transplant, cellular therapy, and a multidisciplinary program that integrates hematology with solid-tumor oncology for patients with combined-pathology cases.
Clinical profile.
Adult and pediatric acute leukemia.
Lymphoma with leukemic presentation.
Myeloma with HSCT indication (covered separately in the BCMA CAR-T myeloma case).
Combined-protocol cases where transplant and solid-tumor management need to run in parallel.
Transplant platforms. Matched sibling, matched unrelated, haploidentical, and autologous. CAR-T for CD19+ and BCMA+ indications is available; T-cell leukemia CAR-T is not a primary focus.
International referral. The strongest fit is for patients already based in or near Shanghai for logistical reasons, or whose care pathway requires coordinated hematology and non-hematology oncology input.
West China Hospital, Sichuan University — Chengdu
West China Hospital is the largest academic medical center in western China and is consistently ranked among the top hospitals in the country by case volume and research output. The hematology service covers the full leukemia indication set and supports a substantial transplant program.
Clinical profile.
Adult and pediatric leukemia across all major subtypes.
MDS and aplastic anemia.
CML in chronic and accelerated phase, including TKI-resistant disease.
Transplant-eligible patients without matched donors, routed through the haploidentical program.
Transplant platforms. Matched sibling, matched unrelated, haploidentical, and autologous. CAR-T is available for the standard CD19 and BCMA indications.
International referral. The practical case for West China is geographic: patients traveling from Australia, New Zealand, or Southeast Asia through western-China routing, or where the Beijing/Shanghai pathway is logistically more difficult. Clinical capability for the major leukemia indications is at parity with the Beijing and Shanghai centers.
Choosing Among the Best Leukemia Hospitals in China
Clinical scenario | Strongest-fit center(s) | Rationale |
Pediatric B-ALL or T-ALL, especially relapsed | Lu Daopei Hospital | Dedicated pediatric hematology; high-volume CAR-T for leukemia |
Adult AML, complex cytogenetics or therapy-related | IHS-CAMS | National-level AML and MDS referral concentration |
Adult ALL, transplant plan with haploidentical donor | Peking University People's Hospital | Reference center for haploidentical transplant |
Pediatric AML with research-protocol eligibility | IHS-CAMS or Lu Daopei | Pediatric AML program depth; CAMS research infrastructure |
Patient already in Shanghai or with combined hematology/oncology needs | Shanghai Ruijin Hospital | Multidisciplinary structure, established international office |
Western-China routing, Australia/NZ/Southeast Asia | West China Hospital, Sichuan University | Geographic fit; full leukemia program |
Relapsed T-cell leukemia, CD7 CAR-T candidate | Lu Daopei Hospital | Concentrated CD7 CAR-T experience |
Donor not available, urgent transplant decision | PUPH or Lu Daopei | Mature haploidentical infrastructure |
For cases that cross categories — relapsed AML with haploidentical donor and CAR-T planning, for example — the right next step is case-by-case triage rather than more reading.
How an International Referral Is Constructed
The mechanics are similar across the five centers:
Case submission. Medical records, pathology reports, recent imaging, HLA typing if available, and a one-paragraph clinical summary go to the hospital's international patient office.
Physician review. A senior hematologist from the relevant leukemia program reviews the case and indicates whether the case fits the center's protocols.
Second-opinion Zoom consult. A 30–45 minute video call with the treating or reviewing physician to discuss the diagnosis, what protocols are realistic, and whether the hospital is the right fit.
reatment plan and itemized quote. Documented plan with protocol, timeline, conditioning regimen, expected stay, and cost.
Visa medical invitation. Issued by the hospital to support an M-class medical visa, typically valid 30–90 days.
Admission. Most allogeneic transplant admissions for international patients run 4–8 weeks depending on donor source and conditioning; CAR-T admissions add apheresis and require at least 30 days of post-infusion monitoring on-site.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
How much does leukemia treatment in China cost for international patients?
Allogeneic HSCT programs typically fall in the USD 60,000–140,000 range depending on donor type and conditioning regimen. CAR-T programs run USD 50,000–120,000. Figures include the hospital stay and standard medications but exclude international travel, accommodation, and any companion-care costs.
Which Chinese hospital is best for pediatric leukemia?
The dedicated pediatric hematology track at Lu Daopei Hospital is the most consistently structured for pediatric B-ALL, T-ALL, and AML. Pediatric AML with research-protocol eligibility also routes through IHS-CAMS, and combined pediatric and adolescent care is run by the leukemia service at West China Hospital. There is no single right answer; subtype and donor availability usually determine the center.
Is CD19 or CD7 CAR-T for leukemia available in China?
Yes. CD19 CAR-T for B-ALL and DLBCL is run at all five centers in this guide. CD7 and CD5 CAR-T for T-ALL is concentrated at Lu Daopei with case-by-case availability elsewhere. T-cell leukemia CAR-T protocols typically require a longer stay and a defined post-infusion monitoring window.
How long from case submission to admission?
For cases with confirmed diagnosis and completed pre-treatment workup, second-opinion Zoom consults are typically scheduled within 5–10 working days from receipt of records, and admission follows within 1–2 weeks of an accepted treatment plan. Urgent cases — post-transplant relapse, refractory disease in a deteriorating patient — can move faster.
Is a consultation without travel to China possible?
Yes. All five centers listed here offer remote second-opinion consults. A document review followed by a Zoom call with the treating physician or a senior member of the leukemia service is the typical starting point. No commitment is implied.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
